Justin Noznesky - AtriCure President
ATRC Stock | USD 23.17 0.46 2.03% |
President
Mr. Justin J. Noznesky is Senior Vice President, Marketing and Business Development of the AtriCure Inc. Previously served as our Vice President, Marketing and Business Development since May 2014 and as our Vice President, Corporationrationrate Development from January 2014 to May 2014. From 2004 to 2013, Mr. Noznesky held progressive financial and business development positions at Vital Images, a subsidiary of Toshiba Medical Systems Corporationrationration, including Vice President, Marketing and Business Development. Prior to working for Vital Images, Mr. Noznesky worked at UnitedHealth Group in Corporationrationrate Finance and at Arthur Andersen LLP as a senior auditor since 2016.
Age | 46 |
Tenure | 8 years |
Address | 7555 Innovation Way, Mason, OH, United States, 45040 |
Phone | 513 755 4100 |
Web | https://www.atricure.com |
Justin Noznesky Latest Insider Activity
Tracking and analyzing the buying and selling activities of Justin Noznesky against AtriCure stock is an integral part of due diligence when investing in AtriCure. Justin Noznesky insider activity provides valuable insight into whether AtriCure is net buyers or sellers over its current business cycle. Note, AtriCure insiders must abide by specific rules, including filing SEC forms every time they buy or sell AtriCure'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Justin Noznesky over three weeks ago Disposition of 1500 shares by Justin Noznesky of AtriCure at 30. subject to Rule 16b-3 |
AtriCure Management Efficiency
The company has return on total asset (ROA) of (0.0324) % which means that it has lost $0.0324 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.066) %, meaning that it created substantial loss on money invested by shareholders. AtriCure's management efficiency ratios could be used to measure how well AtriCure manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to -0.1. In addition to that, Return On Capital Employed is expected to decline to -0.06. At present, AtriCure's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 365.1 M, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
Found 6 records | PRESIDENT Age | ||
Joseph Hauser | Orthopediatrics Corp | 41 | |
Gregory Odle | Orthopediatrics Corp | 54 | |
David Bailey | Orthopediatrics Corp | 45 | |
Francis Casey | Iradimed Co | 62 | |
Daniel Gerritzen | Orthopediatrics Corp | 54 | |
MBAMSHA CHE | Orthopediatrics Corp | 52 |
Management Performance
Return On Equity | -0.066 | ||||
Return On Asset | -0.0324 |
AtriCure Leadership Team
Elected by the shareholders, the AtriCure's board of directors comprises two types of representatives: AtriCure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AtriCure. The board's role is to monitor AtriCure's management team and ensure that shareholders' interests are well served. AtriCure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AtriCure's outside directors are responsible for providing unbiased perspectives on the board's policies.
Salvatore Privitera, CTO | ||
Patricia Kennedy, Vice President General Manager - International | ||
Deborah Yount, Chief Officer | ||
JD CCEP, Chief Officer | ||
CCEP CCEP, Chief Officer | ||
Regina Groves, Independent Director | ||
Scott Drake, Independent Director | ||
Mark Collar, Independent Director | ||
Valerie StorchWillhaus, Vice Communications | ||
Michael Carrel, CEO and President and Director | ||
Mark Lanning, Independent Director | ||
Richard Johnston, Independent Chairman of the Board | ||
Robert White, Independent Director | ||
Sven Wehrwein, Independent Director | ||
Angela CPA, Chief Officer | ||
Elizabeth Krell, Independent Director | ||
Andrew Lux, Sr. VP of Operations and Quality Assurance | ||
Tonya SPHR, VP HR | ||
Vinayak Doraiswamy, Chief Officer | ||
Michael Hooven, Founder and Director | ||
Karen Robards, Independent Director | ||
Salvatore JD, Chief Officer | ||
Justin Noznesky, Senior Vice President Marketing and Business Development | ||
Douglas Seith, Chief Officer | ||
Andrew Wade, CFO, Senior Vice President | ||
Kristine Johnson, Independent Director | ||
Amalio MD, Ex Officer |
AtriCure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AtriCure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.066 | ||||
Return On Asset | -0.0324 | ||||
Profit Margin | (0.08) % | ||||
Operating Margin | (0.12) % | ||||
Current Valuation | 1.03 B | ||||
Shares Outstanding | 48.37 M | ||||
Shares Owned By Insiders | 3.07 % | ||||
Shares Owned By Institutions | 96.93 % | ||||
Number Of Shares Shorted | 3.2 M | ||||
Price To Earning | 33.47 X |
Pair Trading with AtriCure
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AtriCure position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AtriCure will appreciate offsetting losses from the drop in the long position's value.Moving together with AtriCure Stock
0.84 | NRC | National Research Corp | PairCorr |
Moving against AtriCure Stock
0.78 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
0.75 | NXL | Nexalin Technology | PairCorr |
0.67 | IRIX | IRIDEX Financial Report 9th of May 2024 | PairCorr |
0.41 | AGTI | Agiliti Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to AtriCure could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AtriCure when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AtriCure - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AtriCure to buy it.
The correlation of AtriCure is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AtriCure moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AtriCure moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AtriCure can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AtriCure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade AtriCure Stock refer to our How to Trade AtriCure Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for AtriCure Stock analysis
When running AtriCure's price analysis, check to measure AtriCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AtriCure is operating at the current time. Most of AtriCure's value examination focuses on studying past and present price action to predict the probability of AtriCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AtriCure's price. Additionally, you may evaluate how the addition of AtriCure to your portfolios can decrease your overall portfolio volatility.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Transaction History View history of all your transactions and understand their impact on performance | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
CEOs Directory Screen CEOs from public companies around the world | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is AtriCure's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AtriCure. If investors know AtriCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AtriCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.66) | Revenue Per Share 8.621 | Quarterly Revenue Growth 0.21 | Return On Assets (0.03) | Return On Equity (0.07) |
The market value of AtriCure is measured differently than its book value, which is the value of AtriCure that is recorded on the company's balance sheet. Investors also form their own opinion of AtriCure's value that differs from its market value or its book value, called intrinsic value, which is AtriCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AtriCure's market value can be influenced by many factors that don't directly affect AtriCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AtriCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if AtriCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AtriCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.